Current status of autologous breast tumor cell-based vaccines

References

• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
   PubMed Web of Science ®Google Scholar
• NCDB Analytic Cases: disease Site by American Joint Committee on Cancer Stage. National Cancer Data Base (NCDB), Commission on Cancer (CoC), 2013. Available from: https://cromwell.facs.org/BMarks/BMCmp/ver10/Docs/. [Last accessed 1 August 2014]
   Google Scholar
• Weigelt B, Peterse JL, van ’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106
   PubMed Web of Science ®Google Scholar
• Baum M. Harms from breast cancer screening outweigh benefits if death caused by treatment is included. BMJ 2013;346:f385
   PubMed Web of Science ®Google Scholar
• Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 2008;100:1179-83
   PubMedGoogle Scholar
• Disis ML, Stanton SE. Can immunity to breast cancer eliminate residual micrometastases? Clin Cancer Res 2013;19:6398-403
   PubMed Web of Science ®Google Scholar
• Keenan BP, Jaffee EM. Whole cell vaccines–past progress and future strategies. Semin Oncol 2012;39:276-86
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Petrizzo A, Tornesello ML, et al. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011;18:23-34
   PubMedGoogle Scholar
• Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat 2013;138:1-12
   PubMed Web of Science ®Google Scholar
• Slovin SF, Keding SJ, Ragupathi G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol 2005;83:418-28
   PubMed Web of Science ®Google Scholar
• Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010;22:132-43
   PubMed Web of Science ®Google Scholar
• Harrop R, Carroll MW. Viral vectors for cancer immunotherapy. Front Biosci 2006;11:804-17
   PubMed Web of Science ®Google Scholar
• Schatzlein AG. Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 2001;12:275-304
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41
   PubMed Web of Science ®Google Scholar
• Cicchelero L, de Rooster H, Sanders NN. Various ways to improve whole cancer cell vaccines. Expert Rev Vaccines 2014;13:721-35
   PubMed Web of Science ®Google Scholar
• Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vaccines by enhancing cross priming. Cancer Lett 2012;325:155-64
   PubMed Web of Science ®Google Scholar
• Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010;10:52-60
   PubMed Web of Science ®Google Scholar
• Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 1996;85:1261-70
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Alatrash G, Xiao H, et al. Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. Expert Rev Vaccines 2011;10:755-74
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15:e257-67
   PubMed Web of Science ®Google Scholar
• Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74
   PubMed Web of Science ®Google Scholar
• Elliott RL, Head JF, McCoy JL. Comparison of estrogen and progesterone receptor status to lymphocyte immunity against tumor antigens in breast cancer patients. Breast Cancer Res Treat 1994;30:299-304
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Gritzapis AD, et al. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010;2:213-26
   PubMed Web of Science ®Google Scholar
• Srivatsan S, Patel JM, Bozeman EN, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother 2014;10:52-63
   PubMed Web of Science ®Google Scholar
• Elliott RL, Head JF. Adjuvant breast cancer vaccine improves disease specific survival of breast cancer patients with depressed lymphocyte immunity. Surg Oncol 2013;22:172-7
   PubMed Web of Science ®Google Scholar
• Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 2008;31:591-8
   PubMed Web of Science ®Google Scholar
• Hanna MG, Hoover HC, Vermorken JB, et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001;19:2576-82
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot CA, Vermorken JB, Hanna MG, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005;23:2379-87
   PubMed Web of Science ®Google Scholar
• Weiss EM, Meister S, Janko C, et al. High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features. J Immunotoxicol 2010;7:194-204
   PubMed Web of Science ®Google Scholar
• Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010;9:519-25
   PubMed Web of Science ®Google Scholar
• Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer 2007;110:1677-86
   PubMed Web of Science ®Google Scholar
• Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 1997;15:1354-66
   PubMed Web of Science ®Google Scholar
• Jiang XP, Yang DC, Elliott RL, et al. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125–results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 2000;15:495-505
   PubMed Web of Science ®Google Scholar
• Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients (NCT00317603). Available from: clinicaltrials.gov [Last accessed 1 August 2014]
   Google Scholar
• Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer (NCT00880464). Available from: clinicaltrials.gov [Last accessed 1 August 2014]
   Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353:345-50
   PubMed Web of Science ®Google Scholar
• Eager R, Nemunaitis J. GM-CSF gene-transduced tumor vaccines. Mol Ther 2005;12:18-27
   PubMed Web of Science ®Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev 2008;222:287-98
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-31
   PubMed Web of Science ®Google Scholar
• Peng B, Liang L, Chen Z, et al. Autologous tumor vaccine lowering postsurgical recurrent rate of hepatocellular carcinoma. Hepatogastroenterology 2006;53:409-14
   PubMedGoogle Scholar
• Coveney E, Clary B, Iacobucci M, et al. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 1996;120:265-72. discussion 272-263
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Clements VK, Pipeling MR, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol Immunother 2000;49:34-45
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Terman DS, Khan S, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000;60:2710-15
   PubMed Web of Science ®Google Scholar
• Toubaji A, Hill S, Terabe M, et al. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007;25:5882-91
   PubMed Web of Science ®Google Scholar
• Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95
   PubMed Web of Science ®Google Scholar